Death (fetal, neonatal, or later (up to 2 years' corrected age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to 2 years' corrected age))** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Death or cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or cerebral palsy (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Major neurodevelopmental disability at childhood · women at risk of preterm birth (< 34 weeks' gestation)
It is very uncertain whether magnesium sulphate changes major neurodevelopmental disability (school age)** compared with placebo (outcomes (very low certainty).
1 finding from 1 review
Death or major neurodevelopmental disability · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death or major neurodevelopmental disability (up to school age)** compared with placebo (outcomes (low certainty).
2 findings from 1 review
Severe maternal outcome potentially related to treatment (death, respiratory arrest, or cardiac arrest)** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in severe maternal outcome potentially related to treatment (death,… compared with placebo (outcomes (low certainty).
1 finding from 1 review
Adverse effects sufficient to stop treatment · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to higher adverse effects severe enough to stop treatment** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Caesarean section · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in mode of birth (caesarean section)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Postpartum haemorrhage · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in postpartum haemorrhage** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Any breastfeeding at hospital discharge · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Women’s views of treatment** · women at risk of preterm birth (< 34 weeks' gestation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cerebral palsy · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate leads to lower cerebral palsy (up to 2 years' corrected age)** compared with placebo (outcomes (high certainty).
2 findings from 1 review
Major disability by 18 to 24 months corrected age (aligned definition) · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in major neurodevelopmental disability (up to 2 years' corrected age)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Intraventricular haemorrhage, Papile grade 3/4 · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate probably leads to lower severe intraventricular haemorrhage (grade 3 or 4) (newborn/infant)** compared with placebo (outcomes (moderate certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in chronic lung disease/bronchopulmonary dysplasia (newborn/infant)** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Death (fetal, neonatal, or later (up to school age))** · women at risk of preterm birth (< 34 weeks' gestation)
Magnesium sulphate showed no clear difference in death (fetal, neonatal, or later (up to school age))** compared with placebo (outcomes (low certainty).
1 finding from 1 review
Perinatal death or severe morbidity · women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fetal or neonatal mortality · women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Caesarean section · women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Apgar score less than 7 at 5 minutes · women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Low umbilical artery pH (< 7.2 or as defined by trial authors) · women for whom a decision had been made to deliver by caesarean section for suspected fetal distress based on FHR monitoring
It is very uncertain whether summary of findings for subcutaneous terbutaline changes umbilical artery pH < 7.2 compared with IV magnesium sulphate (very low certainty).
1 finding from 1 review